Viewing results 101-125 of 168


Milestones passing by rapidly for Motif Bio

It completed its long-mooted listing on Nasdaq where, some would argue, pharmaceutical companies (and how to value them) are better understood....

on 19/1/17

Motif Bio PLC announces new chief financial officer

Prior to joining Motif Bio, Dickey was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company...

on 18/1/17

Motif Bio successfully raises US$25mln

The firm will receive a net US$21.4mln that will be used to complete the REVIVE-1 phase III clinical studies of its next-generation antibiotic iclaprim....

on 24/11/16

Motif Bio worth 114p, says growth company specialist

The broker reckons the shares are worth 114p, a significant uplift on the 26p they are currently changing hands for....

on 21/11/16

Motif Bio outlines plans to raise US$25mln and join NASDAQ

The fundraiser the AIM-listed drug developer join the NASDAQ exchange that is home to some of America’s largest tech and biotech companies....

on 18/11/16

Sirius and Sound burnish credentials with news market has been waiting for

Sirius Minerals concluded a fundraising, while Sound made a significant gas find ...

on 4/11/16

Motif Bio remains confident over funding

Followers of the company will remember it is in the process of seeking a NASDAQ listing, which would see it raise a significant amount of fresh capital....

on 31/10/16

Amphion adjusts loan terms with Motif Bio

Motif will now make its interest repayments on the US$3.5mln loan in the form of shares and cash, rather than just shares...

on 8/9/16

Motif Bio plc expects data readout earlier than forecast

Patient enrolment is better than expected meaning data readout will come earlier than forecast. Meanwhile, the group also re-negotiates CPN terms with Amphion....

on 8/9/16

Amphion Innovations increases net asset value by 13%

In sterling terms, NAV at the investment company rose to 4.3p per share at the end of June,...

on 7/9/16

Motif Bio flagship superbug drug reaches final stage development

The drug is being developed for the treatment of acute bacterial skin infections and hospital acquired bacterial pneumonia....

on 16/8/16

Motif Bio puts US listing plans on ice

The listing has been put on ice because of market conditions...

on 9/8/16

Broker upgrade for Motif Bio with NASDAQ listing ahead

Analysts at Northlands Capital said there was a “chronic under-investment” in antibiotic resistance....

on 27/7/16

Motif Bio plans to raise up to US$60mln from US investors

Motif says the proceeds will be immediately put to work taking its flagship drug iclaprim through phase III clinical trials....

on 13/7/16

Amphion Innovations surges on Motif float plans

Amphion owns 29.1% of Motif Bio, an AIM-listed group that has a new antibiotic Iclaprim just about to start a phase III trial....

on 13/7/16
Retail & consumer

These pocket rocket superbug stocks could fly

Treasury minister Jim O’Neill is proposing to tax big pharma to pay for much-needed R&D on the next generation of antibiotics....

on 20/5/16

Motif Bio looks to add to drug pipeline

In an update accompanying its prelims, the company, which listed on AIM just over a year ago, also told investors it is developing an oral formulation of iclaprim....

on 20/4/16

Motif Bio adds two new faces to senior team

Pete Meyers comes on board as chief financial officer, and Rajesh Shukla, who has been appointed to the role of vice president, clinical operations....

on 14/4/16

Hopes rise for AIM drug breakthroughs

A trio of AIM companies are putting potential new drugs through phase three trials...

on 26/3/16

Motif Bio PLC invited to prestigious life sciences partnering conference

BIO-Europe Spring is designed to provide top level partnering opportunities for smaller life science companies...

on 23/3/16

Motif doses first patient for phase III trials

In all 1,200 patients will take part in the global trials run by Motif’s partner Covance....

on 2/3/16